Prevalence of oral glucocorticoid usage in the United States: A general population perspective
Top Cited Papers
Open Access
- 17 July 2012
- journal article
- other
- Published by Wiley in Arthritis Care & Research
- Vol. 65 (2), 294-298
- https://doi.org/10.1002/acr.21796
Abstract
Objective There is little information on oral glucocorticoid use in the general US population. Previously, there have been published estimates of glucocorticoid use in countries outside of the US. This study aimed to estimate the prevalence of glucocorticoid use, duration of use, and concomitant use of antiosteoporosis pharmaceuticals in the US population age ≥20 years. Methods Data from 5 cycles (1999–2008) of the National Health and Nutrition Examination Survey (NHANES) were used to provide nationally representative weighted estimates. Oral glucocorticoids and concomitant use of antiosteoporosis pharmaceuticals (bisphosphonates, calcitonin, calcium, hormone replacement therapies, teriparatide, and vitamin D) were analyzed. Results There were 356 NHANES respondents ages ≥20 years who reported use of an oral glucocorticoid in the combined cycles between 1999 and 2008. The weighted prevalence of oral glucocorticoid use was 1.2% (95% confidence interval [95% CI] 1.1–1.4) from 1999–2008, corresponding to 2,513,259 persons in the US. The mean duration of oral glucocorticoid use was 1,605.7 days (95% CI 1,261.2–1,950.1), and 28.8% (95% CI 22.2–35.4) of oral glucocorticoid users reported use for ≥5 years. Concomitant use of a bisphosphonate was reported by 8.6% (95% CI 5.1–11.7) of oral glucocorticoid users, and 37.9% (95% CI 31.7–44.0) reported usage of any antiosteoporosis pharmaceutical. Conclusion Based on NHANES data from 1999–2008, it is estimated that the prevalence of glucocorticoid use in the US is 1.2%, with a long duration of use and infrequent use of antiosteoporotic medications compared to other estimates.This publication has 12 references indexed in Scilit:
- American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid‐induced osteoporosisArthritis Care & Research, 2010
- Practice patterns in patients at risk for glucocorticoid-induced osteoporosisOsteoporosis International, 2005
- Longitudinal patterns in the prevention of osteoporosis in glucocorticoid‐treated patientsArthritis & Rheumatism, 2005
- A Meta-Analysis of Prior Corticosteroid Use and Fracture RiskJournal of Bone and Mineral Research, 2004
- Estimating Hip Fracture Morbidity, Mortality and CostsJournal of the American Geriatrics Society, 2003
- The Epidemiology of Corticosteroid-Induced Osteoporosis: a Meta-analysisOsteoporosis International, 2002
- Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practiceAnnals Of The Rheumatic Diseases, 2002
- Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 updateArthritis & Rheumatism, 2001
- Use of oral corticosteroids in the United KingdomQJM: An International Journal of Medicine, 2000
- Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional studyBMJ, 1996